KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Biocryst Pharmaceuticals (BCRX) over the last 16 years, with Dec 2024 value amounting to $1.1 million.

  • Biocryst Pharmaceuticals' Capital Expenditures rose 6124.62% to $4.0 million in Q4 2015 from the same period last year, while for Dec 2015 it was $5.1 million, marking a year-over-year increase of 4556.36%. This contributed to the annual value of $1.1 million for FY2024, which is 48.15% down from last year.
  • Biocryst Pharmaceuticals' Capital Expenditures amounted to $1.1 million in FY2024, which was down 48.15% from $2.2 million recorded in FY2023.
  • In the past 5 years, Biocryst Pharmaceuticals' Capital Expenditures ranged from a high of $2.4 million in FY2021 and a low of $514,000 during FY2020.
  • For the 3-year period, Biocryst Pharmaceuticals' Capital Expenditures averaged around $1.5 million, with its median value being $1.4 million (2022).
  • As far as peak fluctuations go, Biocryst Pharmaceuticals' Capital Expenditures skyrocketed by 364.01% in 2021, and later plummeted by 48.15% in 2024.
  • Over the past 5 years, Biocryst Pharmaceuticals' Capital Expenditures (MRY) stood at $514,000 in 2020, then soared by 364.01% to $2.4 million in 2021, then tumbled by 43.35% to $1.4 million in 2022, then surged by 60.47% to $2.2 million in 2023, then crashed by 48.15% to $1.1 million in 2024.
  • Its Capital Expenditures stands at $1.1 million for FY2024, versus $2.2 million for FY2023 and $1.4 million for FY2022.